Project Grant R01DK149250
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $899K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham and Women's Hospital Inc. $894,984 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct metabolomics-driven research clarifying the relationship between ultra-processed food consumption and Type 2 Diabetes risk. The project integrates a controlled feeding trial with large-scale epidemiological analyses. A crossover feeding trial will enroll...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded President and Fellows of Harvard College $1,614,202 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to decipher gut microbial metabolism of dietary polyphenols and its impacts on human health and disease. The research will identify and characterize gut microbial enzymes that metabolize multiple classes of polyphenols, elucidate the bioactivities and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas MD Anderson Cancer Center $151,136.00 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct multi-omic analyses of the gut microbiome and its relationship to metabolic dysfunction-associated steatotic liver disease (MASLD). The research integrates metagenomic, metabolomic, and metatranscriptomic analyses to explore microbial...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham & Women's Hospital Inc. $730,898 on July 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate NR5A2 regulatory mechanisms in pancreas health and disease. The research examines how the transcription factor NR5A2 governs acinar cell identity and its role in preventing acinar-to-ductal metaplasia, a reversible process occurring during acute...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $156,510 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on July 1, 2026. The project, "Precision Metabolic Risk Stratification in Depression Via Multi-Omics and EHR," addresses the elevated type 2 diabetes risk in individuals with major depressive disorder, particularly those treated with selective...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $990,000 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a pilot study testing whether polygenic architecture can inform targeted screening and treatment strategies for type 1 and type 2 diabetes. The research implements a genetics-first, recall-by-genotype framework embedded in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham and Women's Hospital Inc. $193,776 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify cytokine biomarkers that predict response to IL-23 p19 inhibitor therapies for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The research will quantify cytokines related to IL-23 signaling in serum and inflamed...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Children's Hospital $831,433 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supporting research to redefine the biogeography and function of food proteins in human health and disease. The project establishes first principles of the food-host interactome by developing systematic approaches to map the transit, transformation, and tissue...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Broad Institute, Inc. $1,647,485 on September 19, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct massive-scale genomic risk assessment across monogenic and common forms of diabetes. The award will support analysis of the largest dataset of rare variation linked to diabetes phenotyping, comprising more than 1.1 million participants (33 percent...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital Corporation (Boston Children's Hospital) $133,500 on July 6, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate integrin αVβ6-mediated activation of latent TGF-β2 in kidney fibrosis. The research will test the hypothesis that integrin αVβ6-mediated TGF-β2 activation drives renal fibrosis and represents a potential therapeutic...